A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

This Phase 1 study evaluates the safety and how the body handles a new investigational drug called LY3549492, which is being explored as a potential treatment for overweight or obesity. Multiple doses are given to assess how the drug is absorbed, distributed, and cleared by the body, and to identify any side effects. Adults with a BMI between 25 and 45 kg/m², no diabetes (HbA1c below 6.5%), and no recent serious cardiovascular events or prior GLP-1 medication use within 3 months may be eligible. Participation lasts approximately 8 weeks and involves receiving daily doses of the study drug and attending clinic visits for blood tests and safety monitoring. This summary was generated by AI to help patients understand the study in plain language.